retatrutide dosing clinical trial VisualAbstract: reduces body weight by 17.5% in patients with obesity retatrutide clinical trial dosing frequency

Recent clinical trials have demonstrated that GLP-1RAs have beneficial effects on renal outcomes, especially in patients with T2D who are at high risk for CVD

The neurotransmitter responsible, as well as the projection sites of the GCG + neurons, is unclear

Interestingly, these benefits may be blunted in the approximately 30% of patients in whom liraglutide increased the resting heart rate (HR) by 10 bpm or more (61)

There is no independent verification, and no details about medical monitoring, dosage consistency, or potential side effects

These medications are intended for people with obesity or those who are overweight with related health issues

In TriNetX, the propensity scores for each patient in both cohorts were obtained by conducting logistic regression on the input matrices